Evaluation of Anti Carcinogenic Activity of Trifolium pratense on Oral Cancer Cell- An in vitro Study

V. A. Muralidharan

Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India.

R. V. Geetha *

Department of Microbiology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India.

*Author to whom correspondence should be addressed.


Abstract

Introduction: Trifolium pratense also known as the red clover is widely distributed in the tropics and in the subtropical regions. It is generally consumed in the form of tea by the northern states of India and some tribal people of Nepal and Bhutan. Studies reveal that it is rich in antioxidant and anti-inflammatory activity. It is due to the presence of unique isoflavones found in Trifolium pratense are Biohanin A and formononetin.

Aim: The main aim of the study is to find out whether Trifolium pratense extract has antiproliferative activity against oral squamous carcinoma cells.

Materials and Methods: The  dried buds of Trifolium pratense flowers  were purchased commercially and then powdered  Then MTT assays  was carried out to find out it’s inhibitory activity against oral carcinoma cells

Results and Discussion: From the assay it is evident that it shows a potent inhibitory activity against oral squamous carcinoma cells. Linear regression analysis revealed that the IC50 was found to be at 53.13µg/ml which is higher than that of other species of this family.

Conclusion: From the above study it is evident that Trifolium pratense has a very good inhibitory activity and hence can be used in the treatment of oral cancer.

Keywords: Trifolium pratense, oral squamous cell carcinoma, anticarcinogenic activity, BiohaninA, MTT assay, innovative technique


How to Cite

Muralidharan, V. A. and Geetha, R. V. (2021) “Evaluation of Anti Carcinogenic Activity of Trifolium pratense on Oral Cancer Cell- An in vitro Study”, Journal of Pharmaceutical Research International, 33(47B), pp. 800–806. doi: 10.9734/jpri/2021/v33i47B33186.